The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Current and future strategies for treatment of glioma
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857 · cited 7×
“For secondary GBM, they are characterized by high levels of IDH1/2 mutations, as above, as well as mutations in ATRX (implies tumors of astrocytic lineage) and mutations in TERT promoter with a co-deletion in 1p19q (suggesting tumors of oligodendroglial lineage) [30].”
BackgroundInfluentialWen, P. Y., & Kesari, S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0708126 · Cited by 3,511
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
The Cancer Genome Atlas Research Network (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402121 · Cited by 3,148
Lacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E., et al. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.95.2.0190 · Cited by 3,091
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834 · cited 2×
“The AVAglio and RTOG 0825 studies were large randomized phase 3 trials that evaluated treatment of Bevacizumab with radiation and Temozolomide in newly diagnosed GBM [57, 58].”
BackgroundBevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma
Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A. F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308345 · Cited by 2,557
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N., Nicholas, M. K., Jensen, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,466
Dolecek, T. A., Propp, J. M., Stroup, N. E., & Kruchko, C. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos218 · Cited by 1,710
An extent of resection threshold for newly diagnosed glioblastomas: Clinical article
Sanai, N., Polley, M.-Y., McDermott, M. W., Parsa, A. T., & Berger, M. S. (2011) · Journal of Neurosurgery · doi:10.3171/2011.2.jns10998 · Cited by 1,646
Self-citationKreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J. A., Camphausen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,577
Cancer stem cells in glioblastoma
Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L. L., & Rich, J. N. (2015) · Genes & Development · doi:10.1101/gad.261982.115 · Cited by 1,520
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Johnson, B. E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C. Y., Fouse, S. D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014) · Science · doi:10.1126/science.1239947 · Cited by 1,362
Self-citationWestphal, M., Hilt, D. C., Bortey, E., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J., & Ram, Z. (2003) · Neuro-Oncology · doi:10.1093/neuonc/5.2.79 · Cited by 1,330
van den Bent, M. J., Brandes, A. A., Taphoorn, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J.-Y., Bernsen, H. J. J. A., Frenay, M., Tijssen, C. C., Grisold, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,226
Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation
Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170
Cairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., Fink, K., Souhami, L., Laperriere, N., Curran, W., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,156
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
van den Bent, M., Afra, D., de Witte, O., Hassel, M. B., Schraub, S., Hoang-Xuan, K., Malmström, P.-O., Collette, L., Piérart, M., Mirimanoff, R., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67070-5 · Cited by 1,035
Structural alterations of the epidermal growth factor receptor gene in human gliomas.
Wong, A. J., Ruppert, J. M., Bigner, S. H., Grzeschik, C. H., Humphrey, P. A., Bigner, D. S., & Vogelstein, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.2965 · Cited by 853
Glioblastoma multiforme: Pathogenesis and treatment
Alifieris, C., & Trafalis, D. T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.05.005 · Cited by 820
Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., Mitchell, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6963 · Cited by 815
McGirt, M. J., Chaichana, K. L., Gathinji, M., Attenello, F. J., Than, K., Olivi, A., Weingart, J. D., Brem, H., & Quiñones-Hinojosa, A. R. (2009) · Journal of Neurosurgery · doi:10.3171/2008.4.17536 · Cited by 809
Franz, D. N., Belousova, E., Sparagana, S., Bebin, E. M., Frost, M., Kuperman, R., Witt, O., Kohrman, M. H., Flamini, J. R., Wu, J. Y., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61134-9 · Cited by 794
Genome-wide association study identifies five susceptibility loci for glioma
Shete, S., Hosking, F. J., Robertson, L. B., Dobbins, S. E., Sanson, M., Malmer, B., Simon, M., Marie, Y., Boisselier, B., Delattre, J.-Y., et al. (2009) · Nature Genetics · doi:10.1038/ng.407 · Cited by 788
Glioblastoma: pathology, molecular mechanisms and markers
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1432-1 · Cited by 735
Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis
Kaur, B., Khwaja, F. W., Severson, E. A., Matheny, S. L., Brat, D. J., & Van Meir, E. G. (2005) · Neuro-Oncology · doi:10.1215/s1152851704001115 · Cited by 725 · cited 1×
“This environment triggers upregulation of hypoxia inducible factors (HIFs) which then promote angiogenesis and cell migration [64].”
BackgroundA vaccine targeting mutant IDH1 induces antitumour immunity
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., et al. (2014) · Nature · doi:10.1038/nature13387 · Cited by 706
Boxerman, J. L., Schmainda, K. M., & Weisskoff, R. M. (2006) · PubMed · Cited by 686
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility
Wrensch, M., Jenkins, R. B., Chang, J. S., Yeh, R.-F., Xiao, Y., Decker, P. A., Ballman, K. V., Berger, M., Buckner, J. C., Chang, S., et al. (2009) · Nature Genetics · doi:10.1038/ng.408 · Cited by 510
Self-citationValtonen, S., Timonen, U. L., Toivanen, P., Kalimo, H., Kivipelto, L., Heiskanen, O., Unsgaard, G., & Kuurne, T. (1997) · Neurosurgery · doi:10.1097/00006123-199707000-00011 · Cited by 426
Westphal, M., Ram, Z., Riddle, V., Hilt, D., Bortey, E., & On behalf of the Executive Committee of the Gliadel® Study Group (2006) · Acta Neurochirurgica · doi:10.1007/s00701-005-0707-z · Cited by 420
Ostrom, Q. T., Gittleman, H., Stetson, L., Virk, S. M., & Barnholtz-Sloan, J. S. (2015) · Cancer Treatment and Research · doi:10.1007/978-3-319-12048-5_1 · Cited by 400
Phuphanich, S., Wheeler, C. J., Rudnick, J. D., Mazer, M., Wang, H., Nuño, M. A., Richardson, J. E., Fan, X., Ji, J., Chu, R. M., et al. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1319-0 · Cited by 388
Humphrey, P. A., Wong, A. J., Vogelstein, B., Zalutsky, M. R., Fuller, G. N., Archer, G. E., Friedman, H. S., Kwatra, M. M., Bigner, S. H., & Bigner, D. D. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.11.4207 · Cited by 382
Wu, J.-S., Zhou, L.-F., Tang, W.-J., Mao, Y., Hu, J., Song, Y.-Y., Hong, X.-N., & Du, G.-H. (2007) · Neurosurgery · doi:10.1227/01.neu.0000303189.80049.ab · Cited by 361
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility
Swedish Low-risk Colorectal Cancer Study Group, Stacey, S. N., Sulem, P., Jonasdottir, A., Masson, G., Gudmundsson, J., Gudbjartsson, D. F., Magnusson, O. T., Gudjonsson, S. A., Sigurgeirsson, B., et al. (2011) · Nature Genetics · doi:10.1038/ng.926 · Cited by 295
Berman, J. I., Berger, M. S., Mukherjee, P., & Henry, R. G. (2004) · Journal of Neurosurgery · doi:10.3171/jns.2004.101.1.0066 · Cited by 264
Self-citationKlein, M., . Taphoorn, M. J. B., Heimans, J. J., van der Ploeg, H. M., Vandertop, W. P., Smit, E. F., Leenstra, S., Tulleken, C. A. F., Boogerd, W., Belderbos, J. S. A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.20.4037 · Cited by 259
T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
Chow, K. K., Naik, S., Kakarla, S., Brawley, V. S., Shaffer, D. R., Yi, Z., Rainusso, N., Wu, M.-F., Liu, H., Kew, Y., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.210 · Cited by 245
Bloch, O., Crane, C. A., Fuks, Y., Kaur, R., Aghi, M. K., Berger, M. S., Butowski, N. A., Chang, S. M., Clarke, J. L., McDermott, M. W., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/not203 · Cited by 241
Self-citationGenome-wide association study of glioma and meta-analysis
Rajaraman, P., Melin, B. S., Wang, Z., McKean-Cowdin, R., Michaud, D. S., Wang, S. S., Bondy, M., Houlston, R., Jenkins, R. B., Wrensch, M., et al. (2012) · Human Genetics · doi:10.1007/s00439-012-1212-0 · Cited by 239
Toward precision medicine in glioblastoma: the promise and the challenges
Prados, M. D., Byron, S. A., Tran, N. L., Phillips, J. J., Molinaro, A. M., Ligon, K. L., Wen, P. Y., Kuhn, J. G., Mellinghoff, I. K., de Groot, J. F., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov031 · Cited by 229
Self-citationBrown, C. E., Starr, R., Aguilar, B., Shami, A. F., Martinez, C., D'Apuzzo, M., Barish, M. E., Forman, S. J., & Jensen, M. C. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1669 · Cited by 225
Walter, K. A., Tamargo, R. J., Olivi, A., Burger, P. C., & Brem, H. (1995) · Neurosurgery · doi:10.1227/00006123-199512000-00013 · Cited by 206
Ulmer, J. L., Hacein-Bey, L., Mathews, V. P., Mueller, W. M., DeYoe, E. A., Prost, R. W., Meyer, G. A., Krouwer, H. G., & Schmainda, K. M. (2004) · Neurosurgery · doi:10.1227/01.neu.0000134384.94749.b2 · Cited by 199
Effect of disease burden on health-related quality of life in patients with malignant gliomas
Osoba, D., Brada, M., Prados, M. D., & Yung, W. K. A. (2000) · Neuro-Oncology · doi:10.1093/neuonc/2.4.221 · Cited by 190
Image guided surgery for the resection of brain tumours
Barone, D. G., Lawrie, T. A., & Hart, M. G. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009685.pub2 · Cited by 183
Franz, D. N., Belousova, E., Sparagana, S., Bebin, E. M., Frost, M., Kuperman, R., Witt, O., Kohrman, M. H., Flamini, J. R., Wu, J. Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70489-9 · Cited by 179
Immunotherapy advances for glioblastoma
Reardon, D. A., Freeman, G., Wu, C., Chiocca, E. A., Wucherpfennig, K. W., Wen, P. Y., Fritsch, E. F., Curry, W. T., Sampson, J. H., & Dranoff, G. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou212 · Cited by 178
Optical innovations in surgery
de Boer, E., Harlaar, N. J., Taruttis, A., Nagengast, W. B., Rosenthal, E. L., Ntziachristos, V, & van Dam, G. M. (2015) · British Journal of Surgery · doi:10.1002/bjs.9713 · Cited by 177
Convection-enhanced delivery for the treatment of glioblastoma
Vogelbaum, M. A., & Aghi, M. K. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou354 · Cited by 167
Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects
Batchelor, T. T., Reardon, D. A., de Groot, J., Wick, W., & Weller, M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0834 · Cited by 165
Chromosome 7p11.2 (EGFR) variation influences glioma risk
Sanson, M., Hosking, F. J., Shete, S., Zelenika, D., Dobbins, S. E., Ma, Y., Enciso-Mora, V., Idbaih, A., Delattre, J.-Y., Hoang-Xuan, K., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr192 · Cited by 163
T cell adoptive immunotherapy of newly diagnosed gliomas.
Plautz, G. E., Miller, D. W., Barnett, G. H., Stevens, G. H., Maffett, S., Kim, J., Cohen, P. A., & Shu, S. (2000) · PubMed · Cited by 159
Impact of brain tumour treatment on quality of life
Heimans, J. J., & Taphoorn, M. J. B. (2002) · Journal of Neurology · doi:10.1007/s00415-002-0839-5 · Cited by 159
Advanced Magnetic Resonance Imaging of the Physical Processes in Human Glioblastoma
Kalpathy–Cramer, J., Gerstner, E. R., Emblem, K. E., Andronesi, O. C., & Rosen, B. R. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0383 · Cited by 157
Regression of Recurrent Malignant Gliomas With Convection-Enhanced Delivery of Topotecan
Bruce, J. N., Fine, R. L., Canoll, P., Yun, J. J., Kennedy, B. C., Rosenfeld, S. S., Sands, S. A., Surapaneni, K. R., Lai, R., Yanes, C. L., et al. (2011) · Neurosurgery · doi:10.1227/neu.0b013e3182233e24 · Cited by 157
Sami, A., & Karsy, M. J. (2013) · Tumor Biology · doi:10.1007/s13277-013-0800-5 · Cited by 151
Systemic T cell adoptive immunotherapy of malignant gliomas
Plautz, G. E., Barnett, G. H., Miller, D. W., Cohen, B. H., Prayson, R. A., Krauss, J. C., Luciano, M. G., Kangisser, D., & Shu, S. (1998) · Journal of neurosurgery · doi:10.3171/jns.1998.89.1.0042 · Cited by 146
Ottenhausen, M., Krieg, S. M., Meyer, B., & Ringel, F. A. (2015) · Neurosurgical FOCUS · doi:10.3171/2014.10.focus14611 · Cited by 145
Fujiwara, N., Sakatani, K., Katayama, Y., Murata, Y., Hoshino, T., Fukaya, C., & Yamamoto, T. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2003.10.042 · Cited by 136
Kong, S., Sengupta, S., Tyler, B., Bais, A. J., Ma, Q., Doucette, S., Zhou, J., Sahin, A., Carter, B. S., Brem, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0319 · Cited by 134
Rg, B., Cs, P., & Wr, S. (1977) · PubMed · Cited by 110
Westphal, M., Hilt, D. C., Bortey, E. B., Delavault, P., Olivares, R., Warnke, P. C., Whittle, I. R., Jääskeläinen, J. E., & Ram, Z. (2003) · Neuro-Oncology · doi:10.1215/s1522851702000236 · Cited by 101
Polymeric drug delivery for the treatment of glioblastoma
Wait, S. D., Prabhu, R. S., Burri, S. H., Atkins, T. G., & Asher, A. L. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou360 · Cited by 91
Quality of life outcomes: measurement and validation.
Df, C. (1996) · PubMed · Cited by 89
Walter, K. A., Tamargo, R. J., Olivi, A., Burger, P. C., & Brem, H. (1995) · Neurosurgery · doi:10.1097/00006123-199512000-00013 · Cited by 68
Buckner, J. C., Pugh, S. L., Shaw, E. G., Gilbert, M. R., Barger, G. R., Coons, S. W., Ricci, P. E., Bullard, D. E., Brown, P. D., Stelzer, K. J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.2000 · Cited by 66
Krings, T., Schreckenberger, M., Rohde, V., Spetzger, U., Sabri, O., Reinges, M. H. T., Hans, F., Meyer, P. T., Möller‐Hartmann, W., Gilsbach, J. M., et al. (2002) · Acta Neurochirurgica · doi:10.1007/s00701-002-0992-8 · Cited by 57
Fluorescence guided resection and glioblastoma in 2015: A review
Leroy, H., Vermandel, M., Lejeune, J.-P., Mordon, S. R., & Reyns, N. (2015) · Lasers in Surgery and Medicine · doi:10.1002/lsm.22359 · Cited by 47
Vaccine therapies for patients with glioblastoma
Sayegh, E. T., Oh, T., Fakurnejad, S., Bloch, O. G., & Parsa, A. T. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1502-6 · Cited by 36
Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme
Ung, N. M., & Yang, I. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1814-1 · Cited by 25
Cited by
Darmanis, S., Sloan, S. A., Croote, D., Mignardi, M., Chernikova, S., Samghababi, P., Zhang, Y., Neff, N., Kowarsky, M., Caneda, C., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.030 · Cited by 997
Self-citationPathological and Molecular Features of Glioblastoma and Its Peritumoral Tissue
D’Alessio, A., Proietti, G., Sica, G., & Scicchitano, B. M. (2019) · Cancers · doi:10.3390/cancers11040469 · Cited by 275
Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment
Andrade, S., Ramalho, M. J., Pereira, M. D. C., & Loureiro, J. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01261 · Cited by 173
Liu, Y., Zou, Y., Feng, C., Lee, A., Yin, J., Chung, R., Park, J. B., Rizos, H., Tao, W., Zheng, M., et al. (2020) · Nano Letters · doi:10.1021/acs.nanolett.9b04683 · Cited by 162
Current status and future perspectives of sonodynamic therapy in glioma treatment.
Wang, X., Jia, Y., Wang, P., Liu, Q., & Zheng, H. (2017) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2017.02.020 · Cited by 86
Metadata
- Authors
- Bush, N. A. O., Chang, S. M., & Berger, M. S.
- Venue
- Neurosurgical Review
- Published
- 2016-04-16
- Volume
- 40
- Issue
- 1
- Pages
- 1-14
- ISSN
- 0344-5607 (ISSN-L)
- 1437-2320
- OpenAlex
- W2341890933
- Cited by
- 577
- References
- 77
- FWCI
- 19.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.